February 5 Office of the Food and Drug Administration USA (Food and Drug Administration - FDA) publ

February 5 Office of the Food and Drug Administration USA (Food and Drug Administration - FDA) published a third quarterly list of drugs, the potential problems with the safe use of which is currently being considered by management. In this case, FDA specified bioluminescence that if the product appears on such a list, it indicates the existence of potential safety problems, but does not mean that the FDA has found a causal link between the use of the drug and the risks.
According to information posted on the website FDA, among other management studies the safety of the means to reduce body weight Xenical / Xenical (Orlistat, Roche ), to which was a high risk of rectal bleeding, and antifungal drug Lamisil / Lamisil (terbinafine " Novartis ), which is considered in relation to the potential risk of side effects from the mind. We also study the risk of hemolytic anemia caused by taking anti-hypertensive medication Diovan / Diovan (valzartan, bioluminescence Novartis ). In addition, management has been studying the risk of birth defects in infants whose mothers took antidepressants, as well as toxic effects on the liver of the drug for the treatment of schizophrenia, Abilify / Abilifay (aripiprazole, Bristol-Myers Squibb ).
Fields marked with an asterisk are required Your Name * Rules of commenting comment to be published after moderation edition of the publication. We reserve the right not to publish posts that are irrelevant to the material and the topic of discussion. Certainly not: - profanity. - Comments that defame the reputation of companies, organizations, products, insults bioluminescence resource users, authors or participants articles. - Incitement to ethnic, religious or other hatred, bioluminescence incitement to unlawful acts; - advertising - posting links to other resources without the consent of a site moderator. E-Mail * Position, Message * Subscribe to new posts Colleagues Filling the example field is required to post comments and is designed to protect Internet resources from spam (junk e-mail messages).
Enter numbers shown in the image * Other articles in this section [11/18/2013 16:58] bioluminescence Clinical research in Ukraine: what to consider when contracting bioluminescence [11/18/2013 bioluminescence 16:52] Ekspertiza materіalіv reєstratsіynogo dosє for lіkarskih zasobіv, lіtsenzovanih tsentralіzovanoyu of procedures for EMA: MOH proponuє sprostiti procedure [15/11/2013 22:49] Specialized Focus Conference "Farmpromotsiya in Ukraine. New Rules - 2013. Current Practice "[11/15/2013 15:39] great reformer. 90th anniversary of the birth of Dmitri Pavlovich Salo [15.11.2013 14:18] The company "Alba Ukraine" announced a change of logo and corporate identity [15/11/2013 12:35] Vipisuvannya retseptіv for INN: Vseukraїnska PHARMACY asotsіatsіya ask vіdmіniti rіshennya Derzhpіdpriєmnitstva [15/11/2013 11:15] Falsifіkovanі Liky: in Marіupolі viyavleno pіdpіlny shop [11/15/2013 10:11] "Zentiva": a generic crown constellation Sanofi [14/11/2013 13:01] Reform the health care system in Ukraine: realities and prospects [11/14/2013 12:33] Porіvnyalnі (referentnі) Kraina schodo sovereign regulyuvannya tsіn on lіkarskі Zasoba: MOH planuє zatverditi order viznachennya їh perelіku Latest News and Articles [18/11/2013 16: 58] Clinical trials in Ukraine: what to consider when contracting [18/11/2013 16:52] Ekspertiza materіalіv reєstratsіynogo dosє for lіkarskih zasobіv, lіtsenzovanih tsentralіzovanoyu of procedures for EMA: MOH proponuє sprostiti procedure [18/11/2013 16:38 ] Draft RESOLVED CMU "On the Introduction for Change to paragraph bioluminescence 2 of the Order derzhavnoї reєstratsії (perereєstratsії) lіkarskih zasobіv" [11/15/2013 23:18] Perelіk preparatіv on yakі DERZHAVNAYA Service of Ukraine s lіkarskih zasobіv seen rozporyadzhennya about zaboronu / dozvіl їh realіzatsії s 11.08.2013 p. on 14.11.2013 p. [11/15/2013 22:49] Specialized Focus Conference "Farmpromotsiya in Ukraine. New Rules - 2013. Current Practice "[11/15/2013 22:22] PANGROL with exocrine insufficiency - a simple answer bioluminescence to a difficult bioluminescence question [11/15/2013 20:13] Rozporyadzhennya od 14.11.2013 p. 24672-1.2/2.0/17-13 [2013-11-15 20:13] Rozporyadzhennya od 14.11.2013 p. 24620-1.3/2.1/17-13 [2013-11-15 bioluminescence 20:13] bioluminescence Rozporyadzhennya od 14.11.2013 p. 24585-1.3/2.0/17-13 [2013-11-15 20:12] Rozporyadzhennya od 13.11.2013 p. 24535-1.3/2.0/17-13 Pharmaceuticals and Pharmacy All News